Metabolic Disorders
TheracosBio’s BRENZAVVY meets primary endpoint in type 2 diabetes trial
TheracosBio has reported data from a Phase III clinical trial where BRENZAVVY (bexagliflozin) as an adjunct to metformin in managing…
Diamyd Medical reaches recruitment milestone in Phase III T1D trial
Diamyd Medical has reported that its Phase III DIAGNODE-3 clinical trial of antigen-specific immunotherapy, Diamyd, in Type 1 Diabetes (T1D)…
Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs
Lipocine hopes its obesity candidate LPCN 2401 could work alongside glucagon-like peptide-1 receptor agonists (GLP1-RAs) to help improve muscle mass…
Eli Lilly begins Phase III trials of oral weight loss drug in India
Eli Lilly has reportedly commenced Phase III clinical trials of oral medication, orforglipron, for weight loss in India. The oral…
89bio wins EMA priority status for MASH candidate pegozafermin
The European Medicine’s Agency (EMA) has granted priority medicines (PRIME) status to 89bio’s pegozafermin, a drug being evaluated to treat…
Viking reports positive data from Phase I oral obesity treatment trial
Viking Therapeutics has reported positive data from its Phase I multiple ascending dose (MAD) clinical trial of VK2735, an oral…
Hua Medicine plans to focus T2D drug on diabetic kidney disease patients
China-based Hua Medicine plans to focus on the US trial development of its type 2 diabetes (T2D) drug in diabetic…
Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints
This week on Pipeline Moves, we kick off by looking at success of a Phase III trial of Ironwood Pharmaceuticals’…
Empros Pharma to dose patients in Phase III obesity trial before end of year
Swedish biopharma Empros Pharma will dose the first subjects with its obesity combination therapy in a Phase III trial before…
89bio kicks off Phase III trial for pegozafermin in MASH
89bio has initiated its Phase III trial ENLIGHTEN-Fibrosis evaluating pegozafermin in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients with…
